A major new milestone has been achieved in the Penta-sponsored clinical trial SMILE, where patient No. 200 has been recruited today. The patient was enrolled at Baylor in Uganda.
Congratulations to all sites for their ongoing committment!
SMILE (also known as PENTA 17) stands for “Strategy for Maintenance of HIV suppression with once daiLy Integrase inhibitor + darunavir/ritonavir in childrEn” and is a multicentre randomised study evaluating safety and antiviral effect of a once daily integrase inhibitor administered with darunavir/ritonavir compared to standard of care among HIV-1 infected, virologically suppressed paediatric participants. 300 children are due to be enrolled in the trial from about 30 sites spread across 14 countries in Europe, Asia, Africa and South America.
The trial is supported by Janssen Pharmaceutica and ViiV Healthcare.